F low diversion is increasingly recognized as an important tool in the treatment of intracranial aneurysms. [3][4][5][6][7][8][9]12 The Pipeline Embolization Device (PED, Covidien) is a flow-diversion device made of 25% platinum tungsten and 75% cobalt chromium.
pophyseal segments. Similarly, concern for branch vessel integrity has resulted in widespread reluctance toward PED use in the posterior circulation where small perforating arteries serve critical brainstem structures. 9 The rate and clinical consequence of branch vessel occlusion after treatment with PEDs remains poorly defined. Recently, authors of small patient series have sought to elucidate this widespread concern, evaluating the rates of ophthalmic artery (OphA), posterior communicating artery (PCoA), and anterior choroidal artery (AChA) integrity following PED placement. 2, 3, 10, 14 In this study, we evaluated the rate of branch vessel patency following PED placement in aneurysms in 82 patients treated at our institution.
Methods
The protocol for this study had the approval of the University at Buffalo institutional review board. Medical records from consecutive patients with anterior circulation aneurysms treated with the PED between 2009 and 2014 were reviewed retrospectively from a prospectively maintained database to obtain demographic data (including age, sex, and medical comorbidities) as well as clinical data regarding complications and outcome. Two investigators who were not involved in the procedures independently reviewed all preprocedure and postprocedure angiographic data, including aneurysm location, number of PEDs deployed, and patency of anterior circulation branch vessels (i.e., OphA, PCoA, AChA, and anterior cerebral artery [ACA]). In situations in which the 2 investigators disagreed on aspects of the angiographic data, discrepancies were reconciled in a blinded fashion by a third investigator.
Our protocol for PED deployment has been described previously.
7 Briefly, patients were pretreated with aspirin (325 mg) and clopidogrel (75 mg) for 5 days prior to treatment. If this was not possible, they were given loading doses (aspirin 650 mg and clopidogrel 600 mg) prior to their procedure. Therapeutic levels were determined using platelet inhibition assays (P2Y12) and aspirin responses (VerifyNow Assay System, Accumetrics, Inc.). Systemic anticoagulation was maintained during the procedure (activated clotting factor > 250 seconds). The patients were subsequently maintained on a regimen of aspirin therapy for life and clopidogrel for at least 6 months. All procedures were performed under conscious sedation and with the use of local anesthetics. All PEDs were deployed using a bi-or triaxial system. A 0.027-inch microcatheter was used to obtain distal access past the segment of the vessel harboring the target aneurysm. The PED was sized to match the maximum diameter of the target vessel. Control digital subtraction angiography (DSA) was performed immediately following PED placement. Follow-up DSA was performed between 3 and 12 months postprocedure. If aneurysm occlusion was confirmed, further follow-up consisted of MRA and was conducted on a yearly basis thereafter. If aneurysm occlusion was not confirmed, yearly DSA was performed until occlusion was confirmed.
Labeling and Indications
According to the US FDA, the PED (study device) is indicated for the endovascular treatment of adults (≥ 22 years of age) with large or giant wide-necked intracranial aneurysms in the ICA from the petrous to the superior hypophyseal segments.
Results
We identified 120 patients who were treated with the PED for aneurysms in the anterior circulation between 2009 and 2014 at our institution. Thirty-eight patients were excluded from analysis for reasons of no branch vessel coverage seen on angiography (n = 21) and lack of follow-up angiography (n = 17). Therefore, we included 82 patients with 82 aneurysms in our subsequent analyses (Table 1 ). Baseline characteristics for these patients including demographics and aneurysm characteristics are presented in Table 2 . The mean aneurysm size was 11.3 ± 6.7 mm. The ophthalmic segment was the most frequent location for aneurysms in our series.
A total of 127 instances of branch vessel coverage were identified in 82 patients with 82 aneurysms (Table 3 ). This included 76 OphAs, 28 PCoAs, 21 AChAs, and 2 ACAs. There was no evidence of branch vessel occlusion immediately after PED deployment. On follow-up angiography (mean 10.0 months, range 3-34.7 months), we identified 13 branch vessel (OphA, PCoA, and ACA) occlusions. The OphA was occluded in 8 of 76 instances (10.5%) (Fig. 1) , the PCoA was occluded in 3 of 28 instances (10.7%) (Fig.  2) , and the ACA in 2 of 2 instances (Fig. 3) . No instance of AChA occlusion was observed on follow-up angiography. Subgroup analysis of PCoA vessel patency showed no occlusion when the PCoA was fetal-type (0 of 4 instances) ( Table 4) . We found a relationship between the number of PEDs deployed and the percentage of branch occlusion (Table 4) . We observed no adverse clinical sequelae in patients who experienced branch vessel occlusion.
Additionally, in an effort to identify factors that correlated with branch vessel occlusion, we analyzed several additional variables in patients with OphA occlusion (Table 5) and those with PCoA or ACA occlusion (Table 6) after PED placement, including aneurysm size and location, number of PEDs used, and use of adjunctive coiling. We found a relationship between the number of PEDs used and the occurrence of branch vessel occlusion ( Table  5) : multiple PEDs were used in 7 of 8 (88%) patients who developed OphA occlusion. Patients with PCoA and ACA occlusion had only 1 PED device placed.
Discussion
Flow diversion is becoming an increasingly used strategy for the treatment of intracranial aneurysms. Flowdiversion devices are supposed to maintain blood flow through parent and branch vessels while disrupting flow into the aneurysm sac. There are concerns regarding possible occlusion of side branches and perforating vessels that unavoidably would be covered by the PED. In our study of 82 patients with 82 intracranial aneurysms treated with PED and 127 instances of branch vessel coverage, we found 13 (15.8%) cases of branch vessel occlusion that included the OphA, PCoA, and ACA. None of these vessel occlusions occurred during or immediately after PED deployment. All occlusions were clinically asymptomatic and were found only on follow-up angiograms. The overall incidence of side branch occlusion has been reported to be between 2.3% and 21%. 3, 4, 10, 12, 14, 15 
Ophthalmic Artery
Of the 76 OphAs covered by PED(s) immediately after PED deployment, we found 8 (10.5%) instances of arterial occlusion over time (Table 5 and Fig. 1 ). None of the 8 patients experienced visual loss. Among these instances, 4 of the patients had 3 PEDs placed, 3 patients had 2 PEDs placed, and only 1 patient had 1 PED placed, suggesting that the number of PEDs used could contribute to branch artery occlusion. Other than the number of PEDs, there were no other risk factors that appeared to increase the risk of OphA branch occlusion. Other variables, such as the presence of the OphA originating from the aneurysm sac, immediate posttreatment intraaneurysmal flow stasis, or patient age, were not significantly correlated. Puffer et al. 10 found similar results when assessing the patency of the OphA in 20 patients after flow-diversion treatment for paraclinoid aneurysms. They found a 21% incidence of OphA occlusion with proximal thrombosis when the OphA was covered with flow-diversion devices. However, their study was limited by the small number of aneurysms treated. Similar to our findings, those events were well tolerated clinically. The OphA has collateral anastomoses with branches of the external carotid artery that could contribute to proximal OphA occlusion if the PED decreases the flow and distal anastomosis takes over endorgan arterial supply. Unlike Puffer et al., we found that the majority of our patients (7 of 8) had 2 or 3 overlapping PED devices. Computational fluid dynamics modeling has shown that after placement of a flow diverter that covers up to 90% of the perforating vessel ostium, flow is reduced only by less than 10% of baseline. 1 Four other studies have shown rates of OphA occlusion after PED deployment that range from 0% to 21%. 10, 12, 14, 15 It would have been interesting to investigate OphA collaterals from the external carotid artery circulation. As the patients remained clinically asymptomatic, one can conclude that there is collateralization.
Posterior Communicating and Anterior Cerebral Arteries
Among the 28 PCoAs covered by PED(s), we observed 3 (10.7%) instances of arterial occlusion at longer-term follow-up (Fig. 2) . All PCoAs were covered by only a single PED device. The 3 patients were asymptomatic (Table  6 ). None of them had decreased flow or occlusion immediately after the procedure. All occlusions were seen at follow-up angiography. Of the 11 cases of the PCoA being covered by a PED, Brinjikji et al. 3 found 5 cases (45%) in which the PCoA was occluded or flow was diminished at a mean follow-up of 12.6 months. None of these patients had clinical symptoms. Vedantam et al. 14 found 1 (7.1%) PCoA occlusion among 11 arteries covered by a PED. In our series, in all 3 instances of PCoA occlusion, the PCoAs were nonfetal-type. Unfortunately, none of the 3 patients had an injection of the vertebral artery to assess for possible retrograde filling of the PCoA.
Regarding the ACA, we found 2 instances of arterial occlusion after PED deployment at follow-up. One patient had a ruptured right ICA bifurcation aneurysm treated with primary coiling. Aneurysm neck recurrence was observed on the 2-year follow-up angiogram. The decision was made to treat the aneurysm recurrence with flow diversion. Because of the aneurysm location, the ACA had to be jailed by the flow diverter. At follow-up angiography performed 10 months after PED treatment, we found that the A 2 artery was not filling from the ipsilateral ACA but from the contralateral ACA through a well-developed an- terior communicating artery (Fig. 3) . The second instance was in a patient with a recurrent large PCoA aneurysm that was treated originally with primary coiling technique. The recurrent aneurysm was treated with flow diversion; similarly, the ACA had to be jailed by the flow diverter. At 7.5 months follow-up after PED treatment, the A 2 was found not to be filling from the ipsilateral ACA but from the contralateral ACA. To the best of our knowledge, there are no previous reports of this phenomenon. Flow diverters placed across the origin of small perforating vessels may maintain flow through the ostium due to a pressure gradient; the same effect may not be true for large collateralrich vessels like the PCoA or ACA. The pressure gradient across the device struts is not enough to maintain flow due to the opposing effect of the collateral flow, which creates a neutral gradient and angiographic occlusion. This observed phenomenon prompts considerations that we should keep in mind when treating aneurysms with flow diverters close to and incorporating large branches. Retrograde flow can also maintain flow into the aneurysm, resulting in no aneurysm occlusion. In these situations, other endovascular techniques, such as stent-assisted coiling or flow diversion with coiling, should be considered.
Anterior Choroidal Artery
Of the 21 AChAs covered by a PED, we did not observe any instance of occlusion (Fig. 3) . Three studies have shown AChA occlusion rates between 0% and 7% after flow diversion with PEDs.
2,14,15 Among 14 patients with the AChA covered by a PED, Brinjikji et al.
2 found 1 occlusion (6.7%) at the time of 6-month follow-up angiography. The patient did not show signs or symptoms of neurological deterioration. As is the case with OphA and PCoA occlusion after PED treatment, collateral flow determines the potential for and clinical significance of vessel occlusion. The lateral posterior choroidal artery, posterior cerebral artery, and PCoA contribute collateral flow to the AChA territory. These collaterals have been observed in cases of chronic ICA occlusion.
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In normal circumstances, terminal arteries without significant collateral supply, such as the AChA, are more likely to remain patent after coverage by a flow diverter. The postulated theory is that the pressure gradient across end arteries is more than that across vessels with a rich collateral supply, thus increasing the threshold for branch occlusion by a flow diverter. Similar to other studies, 10, 12, 14, 15 our results support this theory. Ischemic stroke rates after PED deployment approach 2%, 11,12 and ischemic strokes are more common when giant and posterior circulation aneurysms are treated. These strokes are rarely related to major side branch occlusion. Neurological deficits due to ischemic events are more common within the first 30 days after the procedure. 4 In the current series, none of the patients had any neurological deficits, echoing previous studies findings. Other than multiple PED usage, we were unable to identify any particular risk factors associated with side branch occlusion.
Study Limitations
This study has the inherent limitations of a retrospective study. Patients do not have follow-up MRI to evaluate for clinically silent infarctions potentially related to a branch occlusion. No posterior circulation aneurysms are included.
Conclusions
Results of this large series demonstrated a 15.8% rate of radiographic side branch arterial occlusion after cover- age by a flow diverter. These branches included the ACA, OphA, and PCoA. There were no AChA occlusions. These instances were not associated with any new neurological deficits. The number of PEDs placed seems to correlate with an increased risk of branch occlusion. Branch coverage of richly collateralized vessels is clinically well tolerated.
